Filing Flows › Kyntra Bio (KYNB) › Q2 2025
Kyntra Bio (KYNB) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 11, 2025
Kyntra Bio (KYNB) reported revenue of $1.3M for the second quarter 2025 (Q2 2025), +35% from a year earlier and -51% from the quarter before. Operating margin was -894.1%, net loss $7.6M (564.0% of revenue).
Kyntra Bio, Q2 2025: revenue $1.3M (+35% year over year), operating margin -894.1%, net loss $7.6M, operating cash flow $12.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3M | -51% | +35% |
| Operating profit | −$12.1M | — | — |
| Net earnings | −$7.6M | -264% | — |
| Operating cash flow | $12.7M | +366% | — |
| Free cash flow | $12.7M | +369% | — |
What changed
Revenue was $1.3M in Q2 2025, up 35% year over year and down 51% from the previous quarter. Drug Product Revenue was the largest line at 90% of revenue. Drug Product Revenue added $486K year over year (up 67%), 139% of the total change. Development and Other Revenue declined 51%.
Operating costs exceeded revenue by $12.1M, an operating margin of -894.1%. Total costs fell 72% while revenue rose 35%. The quarter ended with a net loss of $7.6M, after a profit of $4.6M the previous quarter. Non-operating items added $4.4M, -57% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $12.7M. Non-cash charges added back $212K of depreciation and $1.9M of share-based compensation. Working capital and other items added $18.2M. Capital expenditures of $13K left free cash flow of $12.7M.
Questions
What was Kyntra Bio's revenue in the second quarter 2025?
Kyntra Bio (KYNB) reported revenue of $1.3M for the second quarter 2025 (Q2 2025), +35% from a year earlier and -51% from the quarter before.
Was Kyntra Bio profitable in the second quarter 2025?
Operating loss was $12.1M (-894.1% of revenue) and net loss $7.6M.
Source: Kyntra Bio 10-Q on SEC EDGAR.